Funding Round
Sinaptica Therapeutics raises €8M seed extension for personalized Alzheimer's TMS Phase 2
Sofinnova Partners4/5/2026·04/05/26🌐 Europe
Summary
Italian TMS startup Sinaptica Therapeutics secured an €8M extension from Sofinnova Partners ahead of their planned Phase 2 trial of connectome-guided personalized TMS for Alzheimer's disease. The extension bridges to Phase 2 initiation and funds manufacturing scale-up of their individualized neuronavigation-integrated TMS protocol delivery system.
Why it matters
Sofinnova doubling down with an extension before Phase 2 initiation signals high confidence in Sinaptica's approach. The connectome-guided TMS concept has strong scientific backing from the Stanford SCC DBS literature and represents a genuinely differentiated Alzheimer's non-invasive neuromodulation strategy.
#Alzheimers#Neuroimaging#Phase 2#TMS
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in